Form 4: Apogee CMO Exercises Options, Sells Shares

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, executed a pre-arranged trading plan, exercising stock options and subsequently selling common stock.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), engaged in transactions on October 1, 2025.
• Exercised stock options to acquire 2,385 shares of common stock at an exercise price of $22.86 per share.
• Sold 5,110 shares of common stock at a weighted average price of $39.80 per share, with individual sales ranging from $39.33 to $40.04.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 21, 2024.
• Following these transactions, Mr. Dambkowski directly owns 284,733 shares of common stock and 161,625 stock options.
• The stock options represent the right to purchase 175,345 shares, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were executed under a pre-arranged 10b5-1 plan, indicating a planned disposition rather than a reaction to new, non-public information. The insider also realized a profit, which is a positive for the individual but neutral for the company's operational outlook.

Positives

• The Chief Medical Officer realized a profit by exercising options at $22.86 and selling shares at a weighted average price of $39.80.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned disposition rather than a reaction to new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake.

Risks

• No specific risks to the company's operations or financial health were mentioned in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May observe a slight reduction in insider ownership, though mitigated by the 10b5-1 plan. The transactions reflect the Chief Medical Officer monetizing vested equity.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones for the company were mentioned in this filing. The remaining stock options will continue to vest through December 18, 2027, subject to the reporting person's continued service.

Key Dates

Keywords

Apogee Therapeutics, APGE, Carl Dambkowski, Chief Medical Officer, insider trading, Form 4, stock options, share sale, 10b5-1 plan, beneficial ownership